We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dnu3.5
Danuglipron Research
Mostly mechanism / observational
12 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Danuglipron studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 5,766 participants.
Based on 12 studies · 3 meta-analyses · 5 RCTs · 7,220 total participants
Confidence
High confidence
By outcome
Glucose & glycemic controlDose-dependent HbA1c reductions in type-2 diabetes — up to a placebo-adjusted -1.16% at 16 weeks (phase-2b) · Over ~16 weeks
Mostly mechanism / observational11 studies
Weight & obesityPlacebo-adjusted weight loss up to ~-4.2 kg in T2D and -5.0% to -12.9% in obesity over 26-32 weeks, though tolerability limited dosing · Over ~26-32 weeks
Mostly mechanism / observational7 studies
Safety & tolerability
Too few graded studies2 studies
Active research area
12 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysis2026
Li L, Shui D, Zhang X, Tan B, Deng Y · Front Endocrinol (Lausanne) (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
However, both danuglipron and orforglipron were associated with the occurrence of treatment-related adverse events and gastrointestinal adverse events (AEs).
In plain English: Conclusion HiD oral semaglutide and orforglipron demonstrated the most consistent and substantial weight reductions though low-to-moderate certainty and lack of head-to-head comparisons constrain comparative inference.
Kamrul-Hasan ABM, Ashraf H, Nagendra L, Khalil I, Chatterjee S, Dutta D, Haq T, Alanazi MA, Pappachan JM. · Obesity science & practice (2026)
The primary outcome was percent change in body weight, with secondary outcomes including other weight measures and weight thresholds.
All agents except low-dose (LoD) lotiglipron outperformed placebo in percent body weight reduction; high-dose (HiD) semaglutide (MD -11.6%) and orforglipron (MD -11.8%) showed the greatest effects.
Danuglipron HiD, semaglutide HiD, and semaglutide LoD ranked highest for ≥ 5%, ≥ 10%, and ≥ 15% weight loss, respectively.
In plain English: Our review provides a comprehensive overview of the approved and emerging hormone-based AOMs, highlighting the diversity of options that might become available in the near future.
Sidrak WR, Kalra S, Kalhan A. · Indian journal of endocrinology and metabolism (2024)
Tirzepatide, a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, has been observed to be associated with a significant placebo-subtracted weight reduction of 17.8% in a 72-week randomized controlled trial.
Retatrutide, a GLP1R/GCGR/GIPR tri-agonist, has been associated with a placebo-subtracted weight reduction of -22.1% in a 48-week phase-II trial.
Three long-acting GLP1R/glucagon receptor (GCGR) dual agonists, namely Survodutide, Mazdutide, and Pemvidutide, exhibited significant weight loss in clinical trials.
In plain English: These pharmacological agents are having significant impact on glycaemic control and obesity and on their co-morbidities.
Camilleri M, Acosta A. · British journal of pharmacology (2024)
Oral semaglutide (administered daily) is approved for type 2 diabetes mellitus and is on track for regulatory review for obesity.
The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying, which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite.
In the future, it is anticipated that small molecule GLP-1 receptor agonists (e.g., oral danuglipron) will be developed for treating obesity.
In plain English: Novel GLP-1RAs led to significant reduction in HbA1c... (MD = -1.03%)... and significantly higher odds of gastrointestinal, treatment-emergent adverse events (OR = 2.57...) and adverse events leading to discontinuation (OR = 2.89...).
Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. · Metabolism (2023)
Systematic review and random-effects meta-analysis of 7 RCTs (n=1037) of the oral small-molecule GLP-1 agonists orforglipron and danuglipron in T2D and/or obesity
Significant HbA1c reduction (-1.03%) and weight reduction (-3.26 kg in T2D; -7.52 kg in obesity) vs controls; all RCTs low risk of bias (RoB2)
Neutral on severe hypoglycemia and serious adverse events, but ~2.57x higher GI adverse events and ~2.89x higher discontinuation vs controls
In plain English: Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron)... a binding pocket requiring a primate-specific tryptophan 33 residue.
Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, et al. · J Med Chem (2022)
Discovery and medicinal-chemistry paper for PF-06882961 (danuglipron): a 5-fluoropyrimidine chemotype optimized from a sensitized high-throughput screen
A cryo-EM structure and mutagenesis revealed a binding pocket requiring a primate-specific tryptophan-33 residue — explaining insulin increases in primates but not rodents
First single oral dose in healthy humans produced dose-proportional systemic exposure (NCT03309241)